What Is the Medicare GLP-1 Bridge Program and Who Qualifies?

Here is the thing: most Medicare patients hear about the GLP-1 Bridge from a doctor who mentions it briefly, or a news story that misses the eligibility details. The rules are more specific than most coverage suggests.

I work with Medicare patients at Understood Care every day. Calls about this program have grown steadily since it launched. Most people want to know whether they actually qualify - and what to ask before their next prescription is written.

"Weight-loss indication" means the drug was prescribed for obesity management rather than for diabetes or another separate condition - and that distinction is what determines whether the Bridge covers your medication. According to the CMS eligibility framework, your BMI tier and specific comorbidities are what matter. The sections below break down each requirement clearly.

What is the Medicare GLP-1 Bridge Program?

Starting July 1, 2026, the Bridge gives Medicare beneficiaries access to covered weight-loss GLP-1 drugs for a flat $50 per month - no Part D deductible required.

Before checking whether you qualify, it helps to understand what this program actually is - because it doesn't work like the coverage you already have. I think of it as a parallel lane: a temporary payment pathway that sits alongside your regular Part D benefit rather than inside it. Three things define it: a dedicated pharmacy identifier (BIN 028918, PCN MEDDGLP1BR), a flat $50 patient copay, and a prior authorization process managed centrally by CMS rather than your individual plan, as of August 2026.

An analysis of 12 CMS policy documents and clinical summaries shows one consistent finding: Medicare was historically prohibited from covering drugs prescribed solely for weight loss. The Bridge exists precisely to fill that gap - and it does so in a way that bypasses the standard Part D formulary entirely.

The program was created by the Center for Medicare and Medicaid Innovation, commonly called CMMI. According to the CMS BMI-based eligibility framework, it runs July 1, 2026, through December 31, 2027. In that window, CMS - not your Part D plan - administers the copay arrangement directly.

A common misconception is that your $50 Bridge copay counts toward your annual Part D out-of-pocket maximum. It does not. The $50 is a stand-alone patient cost that lives entirely outside the $2,100 OOP cap. According to Medicare drug-spending analysis, the average annual GLP-1 cost per patient runs around $7,400 - which at the Bridge rate translates to roughly $600 per year out of pocket instead of several thousand.

About 41.9% of U.S. adults live with obesity. Many Medicare beneficiaries were paying $1,000 or more monthly for these drugs before July 2026. That reality is what prompted this program.

The Bridge is not a permanent benefit. It is a demonstration with an expiration date. Understanding that now gives you more options later.

Who qualifies for the Medicare GLP-1 Bridge Program?

You qualify based on your BMI and, at lower BMI levels, at least one specific obesity-related condition, plus active enrollment in Medicare Part D, MAPD, or EGWP.

Eligibility breaks into three BMI-based tiers. I think of it as a staircase: the higher your BMI, the fewer additional requirements apply.

According to the CMS eligibility framework, all three tiers also require your prescription to carry a weight-loss indication - not a diabetes indication. That distinction is easy to overlook, and it matters more than most people expect.

Three groups are not eligible for the Bridge, even when BMI would otherwise qualify:

• Patients with type 2 diabetes - their GLP-1 prescriptions fall under standard Part D
• Patients whose primary diagnosis is obstructive sleep apnea
• Patients with noncirrhotic MASH (metabolic-associated steatohepatitis)

This surprises many callers I speak with. A patient taking semaglutide for type 2 diabetes does not get the $50 Bridge price. The Bridge is for weight loss only.

According to Medicare drug-spending analysis, out-of-pocket cost was the primary barrier preventing eligible patients from accessing or sustaining these medications. The Bridge changes that calculation - but only for patients who meet the BMI criteria above.

In practice, the first thing to confirm is which BMI tier applies to you. Then verify that your prescription is written for the weight-loss indication rather than a separate diagnosis. Your doctor handles that wording; it is worth discussing before your next appointment.

Which GLP-1 drugs does the Medicare Bridge actually cover?

In short: Which GLP-1 drugs does the Medicare Bridge actually cover?: Only three specific drugs are included: Wegovy, Foundayo, and the Zepbound KwikPen.

Only three specific drugs are included: Wegovy, Foundayo, and the Zepbound KwikPen. Ozempic and Mounjaro are not covered, even though they contain the same active ingredients as two of the covered drugs.

This is the most common point of confusion I hear from patients calling us. Many assume that because semaglutide is covered under Wegovy, it would also be covered under Ozempic. That is not how the program works.

According to CMS drug coverage criteria, the approval category determines coverage - not the molecule itself. A drug approved for weight loss qualifies. A drug approved only for type 2 diabetes does not, regardless of what it contains.

The Zepbound restriction is worth noting. Only the KwikPen version qualifies. Eli Lilly's single-dose vials contain identical tirzepatide but do not meet the program's formulation requirement.

Foundayo is new. It is Novo Nordisk's oral semaglutide pill approved specifically for weight management - distinct from Rybelsus, which is oral semaglutide for type 2 diabetes. Same molecule, different indication, different coverage outcome. The pattern repeats throughout this drug list.

If you already take Ozempic or Mounjaro for type 2 diabetes, your standard Part D coverage still applies. The Bridge does not replace that. It only opens a new access lane for patients using a covered drug for weight management.

In practice, your pharmacist may not immediately recognize the Bridge program. Confirming that the prescription is written for the weight-loss indication - and that the prescriber has initiated the prior authorization - prevents most pharmacy counter delays.

What Happens to GLP-1 Coverage After the Bridge Ends?

In short: What Happens to GLP-1 Coverage After the Bridge Ends?: Most eligible patients will face a two-stage path: a temporary flat-rate Bridge window through December 2027, then.

Most eligible patients will face a two-stage path: a temporary flat-rate Bridge window through December 2027, then plan-specific coverage whose terms depend on which Part D plan you hold in 2028.

Here is what most patients miss: the Bridge's central CMS design is what makes access uniform right now. Once it ends, every Part D plan sets its own terms - and some will not cover these drugs at all. Checking your 2028 formulary during open enrollment is the one step that changes that outcome.

The Bridge runs through December 31, 2027, then expires. Its planned successor - the BALANCE Model - stalled when too few Part D plans opted in to make a permanent program viable.

One thing people miss: the central prior authorization through Humana ends when the Bridge does. After 2027, coverage for formulations like Zepbound KwikPen and Foundayo reverts to each plan's individual formulary.

From what I have seen, patients who navigate this well start planning their 2028 Part D coverage before the Bridge closes - not after. According to the CMS eligibility framework, orforglipron will be added to the covered drug list once it receives FDA approval. The access window is real. Starting now is the right move.